Compare TransMedics Group Inc (TMDX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Tesla, Inc. — how do they compare? TransMedics Group Inc trades at $86.4 (market cap $3.00B), while Tesla, Inc. trades at $366.01 (market cap $1.45T). The key difference: Tesla, Inc. is far larger — about 483.3× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| TMDX | TSLA | |
|---|---|---|
Market Cap | $3.00B | $1.45T |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $489.88 |
52-Week Low | $61.99 | $298.16 |
Enterprise Value | $3.39B | $1.43T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Tesla (TSLA) trades at $368.16, up 3.98% in the last 24 hours, with a bullish technical signal from moving averages and ADX indicators. Recent earnings show a mix of beats and a miss, with Q2 2026 EPS of $0.33 falling short of the $0.50 estimate. The company's revenue declined to $94.83 billion in 2025, and net income margin compressed to 3.67%, while valuation ratios like P/E of 340.89 remain elevated. Positive news includes regulatory approval for self-driving software in Europe and a surge in German registrations.
Tesla's outlook hinges on execution in autonomous driving and energy segments, but high valuation and margin pressures pose risks. Analyst consensus is mixed with a $398.38 price target, suggesting moderate upside, though competition and demand volatility require caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
